[Ip-health] 24 May 2019 – KEI panel discussion – Assessing the implications of the development of new cell and gene-based therapies (including CAR T and CRISPR): What role should WHO play?

Thiru Balasubramaniam thiru at keionline.org
Tue May 14 09:42:23 PDT 2019


https://www.keionline.org/30769

24 May 2019 – KEI panel discussion – Assessing the implications of the
development of new cell and gene-based therapies (including CAR T and
CRISPR): What role should WHO play?

Posted on May 14, 2019 by Thiru

On Friday, 24 May 2019, Knowledge Ecology International (KEI) will convene
an expert panel, “Assessing the implications of developments in cell and
gene-based therapies (including CAR T and CRISPR): What role should WHO
should play?” from 12h30 to 14h30 in Espace Henry Dunant at the Red Cross
Museum located at Avenue de la Paix 17, Geneva. An example of the potential
role the WHO secretariat could play is producing a report on potential
intellectual property and regulatory barriers for cell and gene-based
therapies including but not limited to CAR T and CRISPR.



*Date: Friday, 24 May 2019Time: 12h30 to 14h30Location: Espace Henry
Dunant, Red Cross Museum, Avenue de la Paix 17, Geneva*

Registration is required. Please contact Thiru Balasubramaniam: thiru[at]
keionline.org or Claire Cassedy: claire.cassedy[at]keionline.org to
register.

Speakers

Dr. Luca Li Bassi, Director General, Agenzia Italiana del Farmaco (AIFA)
Dr. Hannes Braberg, Staff Scientist, University of California, San Francisco
James Love, Director, Knowledge Ecology International (KEI)
Dr. Els Torreele, Executive Director, Médecins Sans Frontières (MSF) Access
Campaign
Salome Meyer, Executive Director, Cancer Alliance

Moderator: Dr Tido von Schoen-Angerer, Board Member, KEI Europe


-- 
Thiru Balasubramaniam
Geneva Representative
Knowledge Ecology International
41 22 791 6727
thiru at keionline.org


More information about the Ip-health mailing list